SCHEMBL2360281

SCHEMBL2360281

CCOC(=O)c1cc(C)n(Cc2cccc(C(=O)N3CCN(C)CC3)c2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.51
TDO2 P48775 2/20 0.51
LMNA P02545 2/20 0.46
FAAH O00519 1/20 0.46
MGLL Q99685 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
PARP1 P09874 4/20 0.44
CNR2 P34972 1/20 0.44
PDE3B Q13370 2/20 0.43
PDE3A Q14432 2/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
TP53 P04637 2/20 0.43
RECQL P46063 1/20 0.43
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2360375 0.88 IDO1 (0.54) IDO1TDO2LMNAFAAHMGLL
SCHEMBL2359577 0.87 IDO1 (0.53) IDO1TDO2LMNAFAAHMGLL
SCHEMBL2358974 0.83 IDO1 (0.52) IDO1TDO2LMNAFAAHMGLL
SCHEMBL2358969 0.83 IDO1 (0.50) IDO1TDO2LMNAFAAHMGLL
SCHEMBL2358971 0.83 IDO1 (0.50) IDO1TDO2LMNAFAAHMGLL
SCHEMBL2360580 0.83 SMN1; SMN2 (0.47) LMNAFAAHSMN1; SMN2ALDH1A1GAA
SCHEMBL2360376 0.81 IDO1 (0.52) IDO1TDO2LMNAFAAHMGLL
SCHEMBL2360734 0.80 IDO1 (0.52) IDO1TDO2LMNAFAAHMGLL
SCHEMBL2364609 0.79 SLC7A5 (0.46) LMNAFAAHSMN1; SMN2RAB9AALDH1A1
SCHEMBL15008945 0.78 CYP3A4 (0.48) IDO1TDO2FAAHMGLLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356113-B1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER IP GMBH (DE) 2015-01-07 EP disclosed
EP-2356113-B1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER IP GMBH (DE) 2015-01-07 EP disclosed
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-08-01 US disclosed
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-08-01 US disclosed
EP-2356113-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-17 EP disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS HIF1AN, HIF1A, VHL IDO1 1109/4885TDO2 1357/4885LMNA 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.